2-氟联苯-3-羧酸 | 103978-23-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟联苯-3-羧酸
• 中文别名: 2′-氟代苯基-3-羧酸；2-氟二苯-3-羧酸
• 英文名称: 2'-fluorobiphenyl-3-carboxylic acid
• 英文别名: 3-(2-fluorophenyl)-benzoic acid；3-(2-Fluorophenyl)benzoic acid
• CAS: 103978-23-0
• 化学式: C₁₃H₉FO₂
• 分子量: 216.212
• InChiKey: KJRAPRROUUCCPO-UHFFFAOYSA-N

物化性质

• 沸点：
  383.0±25.0 °C(Predicted)
• 密度：
  1.261±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2916399090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2'-Fluorobiphenyl-3-Carboxylic Acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 216,21 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2'-Fluorobiphenyl-3-Carboxylic Acid
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2'-Fluorobiphenyl-3-Carboxylic Acid
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  2-氟联苯-3-羧酸 在 potassium nitrate 作用下， 以 硫酸 为溶剂， 以100%的产率得到3-(2-氯-4-硝基-苯基)苯甲酸
  参考文献：
  名称：

  Antibiotic derivatives of

  摘要：

  具有抗菌活性的1-取代-6-氟-7-芳基-(8-氟)-1,4-二氢喹啉-4-酮3-羧酸是通过将相应的烷基1-取代-6-氟-7-溴-(8-氟)-1,4-二氢喹啉-4-酮-3-羧酸酯与芳基金属化合物反应，并水解形成的酯来制备的。

  公开号：

  US04623650A1
• 作为产物：
  描述：

  3-溴苯甲酸甲酯 在 lithium hydroxide 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 甲苯 为溶剂， 反应 29.0h， 生成 2-氟联苯-3-羧酸
  参考文献：
  名称：

  Diflunisal类似物稳定运甲状腺素蛋白的天然状态。有效抑制淀粉样蛋白生成。

  摘要：

  合成了FDA批准的非甾体抗炎药diflunisal的类似物，并将其评估为转甲状腺素蛋白（TTR）聚集（包括淀粉样蛋白原纤维形成）的抑制剂。对于26种化合物观察到高抑制活性。其中，八种在人血浆中对TTR表现出优异的结合选择性（结合化学计量比> 0.50，每个TTR四聚体理论上最多结合有2.0种抑制剂）。生物物理研究表明，这八种抑制剂可在168小时的时间内显着减慢四聚体的解离（淀粉样蛋白生成的速率决定步骤）。这似乎是通过基态稳定化来实现的，这提高了四聚体解离的动力学势垒。这八种抑制剂对WT TTR的动力学稳定作用进一步得到证实，淀粉样蛋白原纤维形成的速率随抑制剂浓度（pH 4.4）的增加而降低。TTR.18（2）和TTR.20（2）配合物的X射线共晶体结构揭示了18和20在TTR结合位点以相反的方向结合。将氟从18的间位移至20的邻位可逆转结合方向，使20的亲水性芳环在外部结合袋中取向，其中羧

  DOI：

  10.1021/jm030347n

文献信息

• Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor
  作者：Shelby C. Yuhas、Daniel J. Laverty、Huijin Lee、Ananya Majumdar、Marc M. Greenberg

  DOI：10.1021/jacs.1c02453

  日期：2021.6.2

  has been closely linked to cancer. Selective inhibitors of this enzyme are lacking. Inspired by DNA lesions produced by antitumor agents that inactivate Pol β, we have undertaken the development of covalent small-molecule inhibitors of this enzyme. Using a two-stage process involving chemically synthesized libraries, we identified a potent irreversible inhibitor (14) of Pol β (KI = 1.8 ± 0.45 μM, kinact

  DNA 聚合酶 β (Pol β) 在 DNA 修复中起着至关重要的作用，并且与癌症密切相关。缺乏这种酶的选择性抑制剂。受使 Pol β 失活的抗肿瘤剂产生的 DNA 损伤的启发，我们着手开发这种酶的共价小分子抑制剂。使用涉及化学合成文库的两阶段过程，我们确定了Pol β的有效不可逆抑制剂 ( 14 ) ( K I = 1.8 ± 0.45 μM, k inact = (7.0 ± 1.0) × 10 –3 s –1 )。抑制剂14比其他 DNA 聚合酶选择性地灭活 Pol β。用14处理的 Pol β 胰蛋白酶消化物的 LC-MS/MS 分析鉴定了聚合酶结合位点内共价修饰的两个赖氨酸，其中一个先前被确定在DNA结合中起作用。荧光各向异性实验表明，用14预处理 Pol β可防止 DNA 结合。在野生型小鼠胚胎成纤维细胞 (MEF) 中使用前抑制剂 ( pro - 14 ) 的实验表明，抑制剂
• A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
  作者：Sundus Akhter、Bjarte Aarmo Lund、Aya Ismael、Manuel Langer、Johan Isaksson、Tony Christopeit、Hanna-Kirsti S. Leiros、Annette Bayer

  DOI：10.1016/j.ejmech.2017.12.085

  日期：2018.2

  β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48

  当在医学界中治疗细菌感染时，β-内酰胺抗生素至关重要。然而，目前它们的效用受到β-内酰胺抗性的出现和扩散的威胁。对β-内酰胺抗生素最普遍的耐药机制是β-内酰胺酶的表达。克服由β-内酰胺酶引起的抗性的一种方法是开发β-内酰胺酶抑制剂，如今临床上已经批准了几种β-内酰胺酶抑制剂，例如阿维巴坦。我们的研究重点是oxacillinase-48（OXA-48），据报道该酶在世界范围内迅速传播，通常在大肠杆菌和肺炎克雷伯菌中得到鉴定。为了指导抑制剂的设计，我们使用了不同取代的3-芳基和3-杂芳基苯甲酸来探测OXA-48的活性位点，以进行有用的酶-抑制剂相互作用。在本研究中，合成了包含49个3-取代的苯甲酸衍生物的聚焦片段文库，并对其进行了生化表征。基于从33片段的酶复合物晶体学数据，片段可以被归类为R 1或R 2个可以通过总体结合构象相对于粘合剂到R的结合1和R 2亚胺培南的侧基。此外，发现了对未来抑
• [EN] NOVEL ANTIFUNGAL PYRIDINYLHYDRAZIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS ANTIFONGIQUES DE PYRIDINYLHYDRAZIDE
  申请人：DAE WOONG PHARMA

  公开号：WO2015034271A1

  公开（公告）日：2015-03-12

  The present invention relates to novel pyridinylhydrazide derivatives and a method for manufacturing the same. The pyridinylhydrazide derivatives of the present invention have excellent antifungal and fungicidal activities, and thus will be useful for the prevention and treatment of various fungal infections. Additionally, the pyridinylhydrazide derivatives of the present invention, unlike other fungicidal preparations, can be orally administered.

  本发明涉及新型吡啶基肼衍生物及其制备方法。本发明的吡啶基肼衍生物具有优异的抗真菌和杀真菌活性，因此可用于预防和治疗各种真菌感染。此外，与其他真菌杀菌制剂不同，本发明的吡啶基肼衍生物可以口服。
• METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES
  申请人：KELLY Jeffery W.

  公开号：US20120065237A1

  公开（公告）日：2012-03-15

  Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.

  动力学稳定化甲状腺素转运蛋白的天然状态是防止蛋白质错误折叠的有效机制。因为甲状腺素转运蛋白的错误折叠在甲状腺素转运蛋白淀粉样疾病中扮演重要角色，抑制这种错误折叠可以用作有效的治疗或预防这种疾病的方法。本文公开了治疗方法。
• [EN] GUANIDINE DERIVATIVES AS INHIBITORS OF Na/H EXCHANGE IN CELLS<br/>[FR] DERIVES DE GUANIDINE, UTILISES COMME INHIBITEURS DE L'ECHANGE DE Na/H DANS LES CELLULES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1994026709A1

  公开（公告）日：1994-11-24

  (EN) Guanidine derivatives of formula (I), wherein Y is N or C-R1 (in which R1 is hydrogen, lower alkyl, hydroxy, protected hydroxy, etc.), R2 is hydrogen, aryl which may have one suitable substituent, aryloxy, etc., R3 is hydrogen, lower alkoxy, hydroxy, protected hydroxy, etc., Z is N or C-R4 (in which R4 is hydrogen, carboxy, protected carboxy, nitro, halogen, hydroxy(lower)alkyl, etc.), and W is N or C-R12 (in which R12 is hydrogen, lower alkoxy, nitro, hydroxy or protected hydroxy), and pharmaceutically acceptable salts thereof which are useful as a medicament.(FR) L'invention se rapporte à des dérivés de guanidine, représentés par la formule (I), où Y représente N ou C-R1 (où R1 représente hydrogène, alkyle inférieur, hydroxy, hydroxy protégé, etc.), R2 représente hydrogène, aryle qui peut comporter un substituant approprié, aryloxy, etc., R3 représente hydrogène, alcoxy inférieur, hydroxy, hydroxy protégé, etc., Z représente N ou C-R4 (où R4 représente hydrogène, carboxy, carboxy protégé, nitro, halogène, hydroxy alkyle (inférieur), etc.), et W représente N ou C-R12 (où R12 représente hydrogène, alcoxy inférieur, nitro, hydroxy ou hydroxy protégé), ainsi qu'à des sels pharmaceutiquement acceptables de ces dérivés, utiles comme médicaments.

  (中) 公式(I)中的guanidine衍生物，其中Y是N或C-R1（其中R1是氢，低烷基，羟基，保护羟基等），R2是氢，芳基（可能有一个适当的取代基），芳氧基等，R3是氢，低烷氧基，羟基，保护羟基等，Z是N或C-R4（其中R4是氢，羧基，保护羧基，硝基，卤素，羟基（低）烷基等），W是N或C-R12（其中R12是氢，低烷氧基，硝基，羟基或保护羟基），以及其药学上可接受的盐，可用作药物。